A Partnership of Excellence


Merck Animal Health is the trusted leader and advocate for disease prevention. From disease research and clinical studies, to the proven efficacy of Nobivac® vaccines, Merck Animal Health is always striving to help you keep pets safe.

A History of Nobivac®

Through Merck Animal Health, Nobivac® has made significant contributions to the development and innovation of vaccines – enabling essential progress for animal health over the decades.


Nobivac® Parvo: a revolution in canine vaccination. The first high titer, low passage vaccine against Canine Parvovirus (CPV) and the first to break through levels of maternally derived antibodies to allow puppies to complete their primary course vaccinations at 12 weeks of age.


Nobivac® Parvo 2b: relevant protection where you need it. The first parvo 2b strain incorporated in a vaccine.

Nobivac® (Intra-Trac®) KC: first and only intranasal vaccine approved for use in pregnant bitches.


Nobivac® Tricat: first feline vaccine shown to cross-protect against CPV.


Nobivac® Feline Bb: the world’s first vaccine to protect cats against Bordetella bronchiseptica.


Nobivac® DHPPi / DHP – 3 year DOI: the first vaccines against CDV, CAV and CPV with a proven 3 year duration of immunity. The claim was first launched in the UK, followed by USDA approval for the US in 2005.


Nobivac® Parvo – cross-protection against CPV type 2c: the first parvovirus vaccine with published evidence of complete protection against the newly-emerged CPV type 2c

Nobivac® Feline 3-HCP: the first and only feline trivalent core vaccine approved for 3 year duration of immunity.


Nobivac® Canine Flu: the first canine influenza vaccine against the newly emerged H3N8 virus.

Nobivac® Lyme: the first Lyme disease vaccine specifically designed to trigger borreliacidal antibodies against two Borrelia burgdorferi antigens, OspA and OspC.


Nobivac® FeLV 2 year DOI: the first FeLV vaccine that provides a 2 year duration of immunity.


Nobivac® Lepto4: the first 4-way leptospirosis vaccine indicated to aid in the prevention of disease, mortality and urinary shedding caused by all 4 serovars.


Nobivac® Canine Flu H3N2: the first fully licensed vaccine to protect dogs against the new canine influenza virus strain H3N2.

Nobivac® Canine Flu Bivalent: the first fully licensed vaccine to protect dogs against both known strains of canine influenza virus H3N8 and H3N2.

Nobivac® Intra-Trac Oral Bb: is the first oral Bordetella vaccine proven by a real time duration of immunity study to protect dogs for 1 year against canine cough caused by Bordetella bronchiseptica.


Nobivac® EDGE
introduced the first 0.5 mL lepto vaccine shown effective against disease, mortality and leptospiria as well as the first 0.5 mL combo vaccine to protect against parainfluenza.

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

COVID-19 Nobivac® Relief Plan

Program Detailer

Merck Animal Health recognizes these are challenging times. While we practice physical and social distancing, many dogs and cats in the United States may be late returning for vaccination. Considering this unexpected situation, Merck Animal Health is pleased to introduce the COVID-19 Nobivac® Relief Plan.  

View Program

Nobivac® Social Media Kits

Digital Assets

Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.


The Infectious Disease Handbook

Stay on top of preventive care, and keep your business free from an outbreak, with this free handbook.


No items to show.



View All Nobivac References